Multicenter open label, randomized Phase 2 trial of varlitinib versus lapatinib in combination with capecitabine in patients with HER2+ metastatic breast cancer (MBC) who failed prior trastuzumab therapy.
S.C. Lee, S.C. Chen, M.S. Dai, G.E. Lee, C.L. Liu, A. Chan, H.K. Chang, L.M. Tseng, W.Y. Chay, L.W.C. Chow, J.L. Peneyra, K.M. Rau, H.C. Wang, A.A. Guancia, M. Head, J.W.Y. Chiu, B. Robinson, M. McHale, A. Barge, B. Lindmark, N. McIntyre, C.Y. Hsieh.
ESMO Asia (2017), Abstract Number 102P.
Initial signals of efficacy in cholangiocarcinoma from a phase Ib trial of varlitinib in combination with doublet chemotherapy (cisplatin + 5-fluororacil or capecitabine).
C.Y. Hsieh, M.S. Wu, M. McHale, B. Lindmark, L. Chow, Y. Chao.
ASCO (2017), Abstract Number e15671.
Pan-HER inhibitor, varlitinib (ASLAN001) disrupts HER/ERK signaling and causes apoptosis in triple negative breast cancer cells.
C.Y. Liu, T.T. Huang, C.T. Huang, H.P. Yang, L.M. Tseng, C.W. Shiau, K.F. Chen.
AACR (2017), Abstract Number 2087.
Varlitinib to demonstrate anti-tumour efficacy in patient-derived hepatocellular carcinoma xenograft models.
C.Y. Hsieh, L. Ooi, R. Ong, B. Lindmark, M. McHale, H.T. Huynh.
ASCO (2016), Abstract Number e15598.
Varlitinib demonstrates potent antitumour efficacy in patient-derived gastric cancer xenograft models.
H.T. Huynh, R. Ong, B. Lindmark, M. McHale, A.G.L. Ooi.
AACR (2016), Abstract Number 4719.
Phase IIA study to evaluate the biological activity of varlitinib (ASLAN001) in HER-1/2 co-expressing or HER-2 amplified advanced gastric cancer.
J. Kim, S. Im, K. Lee, J.W. Kim, K. Lee, S. Han, T. Kim, I.S. Choi, D. Oh, N. Lee, C. Song, M. Foster, M. McHale, A. Barge, W.H. Kim, Y. Bang
ESMO (2014), Abstract Number 664P.
Pan-ErbB inhibition by varlitinib (ARRY-334543) is superior to selective ErbB inhibition in a preclinical model that signals through multiple ErbB receptors.
R.Blackwell, K. Bouhana, S. Winski, P. Lee, J. Winkler, D. Walker, J. Garrus.
AACR (2010), Abstract Number 3610.
In vivo activity of varlitinib (ARRY-334543), a potent, small molecule inhibitor of EGFR/ErbB-2 in combination with trastuzumab, capecitabine or docetaxel.
D. Anderson, C. Napier, A. Avrutskaya, A. White, T. Pheneger, J. Winkler, P. Lee.
AACR (2009), Abstract Number 1757
Differential activity of varlitinib (ARRY-543), a potent, small molecule inhibitor of EGFR/ErbB2 compared to lapatinib in in vivo xenograft models.
K.Bouhana, T. Pheneger, R. Woessner, G. Tarlton, I.V. Carlowitz, K. Hoffman, E. Wallace, K. Koch, J. Winkler, S. Winski, P. Lee.
AACR (2008). Abstract Number 4848.
In vivo activity of varlitinib (ARRY-334543), a potent, small molecule inhibitor of EGFR/ErbB-2 in combination with trastuzumab or docetaxel.
P.Lee, D. Anderson, A. Avrutskaya, A. White, T. Pheneger, J. Winkler.
CTRC-AACR San Antonio Breast Cancer Symposium (2008). Abstract Number 2150.
In vivo anti-tumour activity of varlitinib (ARRY-334543), a small molecule inhibitor of EGFR and ErbB-2.
T.Pheneger, R. Woessner, S. Winski, D. Anderson, J. Lyssikatos, B. Bernat, G. Miknis, G. Topalov, L. Ren, E. Wallace, P. Lee.
AACR-NCI-EORTC (2005). Abstract Number A247.
Varlitinib (ARRY-334543), a potent, orally active small molecule inhibitor of EGFR and ErbB-2.
G.Miknis, E. Wallace, J. Lyssikatos, P. Lee, Q. Zhao, J. Hans, G. Topalov, A. Buckmelter, G. Tarlton, L. Ren, J. Tullis, B. Bernat, L.P. Opie, I.V. Carlowitz, J. Parry, T. Morales, M. Perrier, R. Woessner, T. Pheneger, K. Hoffman, J. Winkler, K. Koch.
AACR (2005). Abstract Number 3399.